Kiran Mazumdar-Shaw backs India biotech expansion, calls for private follow-on capital

India’s biotechnology sector has established a solid foundation for groundbreaking medical research, but scaling these innovations into global commercial successes will require deeper private venture capital and quicker exit pathways for investors, according to Biocon Chairperson Kiran Mazumdar-Shaw.

Speaking on social media and at recent industry forums, the veteran industrialist pointed out that public policy interventions have already transformed the availability of seed capital across the country. Government initiatives designed to foster advanced research have enabled dozens of early-stage firms to move from conceptual laboratories to viable product development.

Government policy builds the innovation bedrock

India has made a clear transition from focusing primarily on generic pharmaceuticals to advancing high-value drug innovation, Mazumdar-Shaw noted. Targeted state schemes have played a pivotal role in absorbing early R&D risks and giving young enterprises room to experiment.

These flagship programmes have successfully established early-stage and risk funding mechanisms. "Government has basically committed itself to providing the early-stage capital, the risk capital, the seed capital," Mazumdar-Shaw said. "And I think that's going to help a lot of innovative companies and startups to start doing interesting things."

Unlocking private capital for full commercial scale

While state backing has successfully built a pool of promising life sciences ventures, sustained growth requires private institutional capital to take over in the growth phases. Mazumdar-Shaw stressed that private venture capital funds need faster exit mechanisms to feel confident putting money into long-term clinical development cycles.

In biotech, where product development can span several years due to clinical trials and regulatory reviews, venture funds require visible horizon exits to churn capital back into new discoveries.

"What we need now is to ensure the follow-on funding, and creating clearer exit opportunities for investors and according innovation the value it deserves," Mazumdar-Shaw wrote on X on 19 October 2026. "Getting these fundamentals right is key to building a strong biotech ecosystem and turning scientific discoveries into successful businesses."

Earlier in October at the Bloomberg New Economy Forum, she noted that the absence of rapid exit timelines remains a primary reason venture firms hesitate on secondary funding rounds. As India strengthens its intellectual property frameworks and financial market depth, matching early-stage public backing with mature private capital markets remains the final step to establishing India as a global biotechnology powerhouse.